{"public_id":"co_3bd3d4bf89ff5a507c813972c730a52f","status":"active","merged_into_public_id":null,"resolved_public_id":"co_3bd3d4bf89ff5a507c813972c730a52f","name":"matrix or coating material","description":"A formulation component used to form the bulk matrix of a dosage form or to coat its surface.","aliases":["matrix","coating material"],"types":["excipient","formulation component"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":97106121,"title":"Pharmaceutical use of galactomannans","citation_count":46,"url":"https://sah.borca.ai/papers/97106121"}],"claims":[{"public_id":"cl_43c2667a902d1d590e04e139d80661e6","text":"Galactomannans are used not only as inert excipients but also to modify drug release, especially in colonic environments, as matrix or coating materials.","corpus_id":97106121,"url":"https://sah.borca.ai/claims/cl_43c2667a902d1d590e04e139d80661e6"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_3bd3d4bf89ff5a507c813972c730a52f","url":"https://sah.borca.ai/concepts/co_3bd3d4bf89ff5a507c813972c730a52f"}